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Abstract
The surface component b-dystroglycan is a member of the dystrophin–glycoprotein complex providing a trans-sarco-
lemmal linkage between the actin membrane cytoskeleton and the extracellular matrix component laminin-a 2. Although
abnormalities in this complex are involved in the pathophysiology of various neuromuscular disorders, little is known about
the organization of dystrophin-associated glycoproteins in diaphragm and brain. We therefore investigated the oligomeriza-
tion of b-dystroglycan and its connection with the most abundant dystrophin homologues in these two tissues. Employing
detergent solubilization and alkaline extraction procedures of native membranes, it was confirmed that b-dystroglycan
behaves like an integral surface molecule as predicted by its cDNA sequence. Immunoblot analysis following chemical
crosslinking of native membranes showed that b-dystroglycan has a tendency to form high-molecular-mass complexes.
Within these crosslinkable complexes, immuno-reactive overlaps were observed between b-dystroglycan, a-dystroglycan,
laminin and 427 kDa dystrophin in diaphragm and skeletal muscle. In synaptosomes, the major brain dystrophin isoform
Dp116 also exhibited an immuno-reactive overlap with members of the dystroglycan complex. These findings demonstrate
that b-dystroglycan does not exist as a monomer in native membranes and imply that certain dystrophin isoforms and
dystrophin-associated components interact with this surface protein in diaphragm and brain as has been previously shown
for skeletal and heart muscle. q 1998 Elsevier Science B.V.
Keywords: Dystroglycan; Dystrophin; Dp-116; Dystrophin–glycoprotein complex; Laminin; Crosslinking
1. Introduction
Dystrophin, initially identified as the primary de-
w xfect in DuchennerBecker muscular dystrophy 1 , is
now well established to be associated with a variety
w xof surface proteins 2,3 and was shown to exist in
numerous isoforms in many tissues including brain
w x4,5 . Dystrophin-associated components belonging to
the highly glycosylated surface dystroglycan-complex
) Corresponding author. Fax: q353-1-269-2749; E-mail:
kay.ohlendieck@ucd.ie
are proposed to provide a trans-sarcolemmal linkage
between the basement membrane component laminin-
a 2 and the actin membrane cytoskeleton in skeletal
w xmuscle fibres 6–9 . While peripheral a-dystroglycan
of apparent 156 kDa represents a novel non-integrin
class of laminin-binding proteins, 43 kDa b-dys-
troglycan is an integral dystrophin-associated glyco-
w xprotein 10 . Both dystroglycan proteins are encoded
by a single gene whose expressed precursor protein
product is post-translationally processed into two
w xglycoproteins 11,12 . Molecular studies have shown
that the extreme COOH-terminus of b-dystroglycan
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constitutes a unique binding site for the second half
of the hinge-4 region and the cysteine-rich domain of
w xdystrophin 13 and that a-dystroglycan can interact
with the a 2-chain of laminin-2, formerly referred to
w xas merosin 11,14,15 . Both proteins co-localize with
w xdystrophin to the muscle surface 16–18 , clearly
co-purify in subcellular fraction studies with the sar-
w xcolemma fraction 16,19 and contain asparagine-lin-
w xked oligosaccharides 20 . Serinerthreonine-linked
oligosaccharides on a-sarcoglycan are proposed to
confer a stiff conformation to the peptide core and
protease resistance to this peripheral cell surface pro-
w xtein 20 . Although the principal sub-plasmalemmal
cytoskeleton link to the basement membrane is prob-
ably provided by these two tightly associated dystro-
glycans, other sarcolemmal proteins might also be
involved in this process, i.e., components of the
sarcoglycan sub-complex ranging in relative molecu-
w xlar mass from apparent 25 kDa to 50 kDa 2,3 .
Following the detailed analysis of the spatial con-
figuration of the muscle dystrophin–glycoprotein
complex, it was established that primary or secondary
defects in the dystrophin–glycoprotein complex lead
to a variety of neuromuscular disorders, i.e.,
DuchennerBecker muscular dystrophy, congenital
muscular dystrophy and certain forms of limb-girdle
w xmuscular dystrophy 8,9,21–24 . Recently, b-dys-
troglycan was described as defective in a novel form
w xof muscular dystrophy 25 . However, although a
large number of patients afflicted with Duchenne
muscular dystrophy suffer from respiratory complica-
w xtions 26 , relatively little work has been done on the
biochemical and pathophysiological characterization
of dystrophin-associated components in the di-
aphragm. In addition, the association of brain dys-
trophins with other neuronal surface components is
not well understood and the normal function and
potential involvement of these isoforms in brain dis-
orders is mostly unknown. Since one third of
Duchenne patients suffer from non-progressive men-
tal retardation, mutations in brain dystrophins may be
the primary or contributing factor leading to these
w xclinical symptoms 27–29 .
Brain dystrophin of 427 kDa has been localised to
w xthe postsynaptic density 27 and is present in a wide
range of neurons including cerebellar Purkinje cells
w xand pyramidal neurons in the cerebral cortex 30,31 .
Recently, we could show that the major brain dys-
trophin isoform Dp116 exhibits biochemical proper-
w xties typical of a membrane cytoskeletal protein 32 .
Thus, although Dp116 is lacking the N-terminal
actin-binding domain of 427 kDa dystrophin, it ap-
pears to be a component of the sub-plasma membrane
cytoskeleton possibly involved in anchoring proteins
in the periphery of neurons. Another member of the
superfamily of spectrin-like components, autosoma-
lly-encoded utrophin of 395 kDa, has an even broader
w xdistribution in brain 33 and may function in the
generation and maintenance of regional substratum-
associated membrane specialisations at the blood–
w xbrain barrier 34 . Utrophin was originally described
as a neuromuscular junction-specific dystrophin iso-
w xform 35–37 . Since the utrophin-associated compo-
nent a-dystroglycan was found to be a functional
agrin-receptor, the utrophin–glycoprotein complex is
implicated in the anchoring of the nicotinic acetyl-
wcholine receptor at the neuromuscular junction 38–
x40 . Although a- and g-sarcoglycan appear to be
w xmuscle-specific proteins 41 , other dystrophin-asso-
ciated proteins were clearly established to be present
w xin neuronal tissues 42–45 . In neural retina, the
dystroglycan complex is expressed in the inner limit-
ing membrane and around blood vessels where it
w xco-localises with laminin and utrophin 43 . Both
dystroglycans are also present in the outer plexiform
layer of retina, which is devoid of laminin, but
w xcontains dystrophin and utrophin 43 . Studies by
w xMummery et al. 42 showed that b-dystroglycan is
enriched in synaptic membranes of adult rat forebrain
and that a novel b-dystroglycan-related protein of
apparent 164 kDa is enriched in the postsynaptic
density. In addition, analysis of dystrophin-associated
w xproteins in rat cerebellum by Tian et al. 44 support
the hypothesis that dystrophin interacts with dystro-
glycans in Purkinje neurons. Binding studies with
purified brain a-dystroglycan established that it can
w xinteract with a 2-chain-containing laminin-2 44 . In
addition, syntrophins were recently shown to co-
localize with various dystrophin isoforms and dystro-
w xglycans in mouse brain 45 .
Biochemical evidence for a tight association be-
tween skeletal muscle surface glycoproteins and dys-
trophin isoforms exists from chromatographic tech-
niques, analytical gradient centrifugation and domain
w xbinding studies 2,3,13,15,20 . Although the dys-
trophin–glycoprotein complex can be isolated by
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laminin affinity columns and labeled laminin binds
w xstrongly to a-dystroglycan in overlay assays 11,15 ,
the purified skeletal muscle dystrophin–glycoprotein
complex contains no detectable laminin-a 2 chain
w x2,3 . This loss in laminin-a 2 may be due to break-
age of weak non-covalent bonds during salt washes
to remove actomyosin contaminations from vesicular
muscle membrane preparations. Thus, to more di-
rectly determine the oligomerization of the principal
trans-sarcolemma spanning component of the dys-
trophin–glycoprotein complex, b-dystroglycan, and
its association with laminin isoforms and dystrophin,
we performed a chemical crosslinking analysis. This
is an extremely powerful technique for the determina-
tion of tight neighborhood relationships between
w xmembrane proteins 46 and this method was ex-
ploited in this study to investigate potential protein–
protein interactions between key components of the
dystrophin–glycoprotein complex in diaphragm and
brain. Crosslinking analysis was performed under
˚w xoptimized conditions 47 with the hydrophobic 12 A
w xcrosslinker dithiobis-succinimidyl propionate 48 and
changes in the electrophoretic mobility of compo-
nents of the diaphragm and brain dystrophin–glyco-
protein complex were determined using immuno-
blotting with highly specific antibodies to b-dys-
troglycan, a-dystroglycan, laminin, dystrophin and
Dp116.
2. Experimental procedures
2.1. Materials
Dithiobis-succinimidyl propionate was obtained
 .from Pierce & Warriner Chester, Chesire, UK . Per-
oxidase-conjugated and fluorescein-labeled secondary
antibodies to rabbit or mouse IgG, as well as chemi-
cals for enhanced chemiluminescence detection and
protease inhibitors were purchased from Boehringer
 .Mannheim Lewis, East Sussex, UK . Immobilon-NC
nitrocellulose was from Millipore Bedford, MA,
.USA . All other chemicals were of analytical grade
and purchased from Sigma Chemical Company
 .Poole, Dorset, UK .
2.2. Antibodies
Affinity-purified, polyclonal antibodies to the ex-
treme COOH-terminus of dystrophin, which recog-
nize the major brain isoform Dp116, were produced
w xas previously described in detail 32 . Polyclonal
antibody to crude laminin preparations from base-
 .ment membranes of Englebreth–Holm–Swarm EHS
mouse sarcoma, monoclonal antibody VC1.1 to the
HNK-1 antigen, as well as monoclonal antibody SB-
SP-1 to human erythrocyte spectrin were purchased
 .from Sigma Chemical Company Poole, Dorset, UK .
The laminin antibody, although produced against
 . w xlaminin-1 previously named EHS-laminin 49 , rec-
ognizes both laminin-1 and laminin-2 previously
. w xnamed merosin 49 isoforms. Monoclonal antibody
NCL-43 to b-dystroglycan was from Novocastra
 .Laboratories Newcastle upon Tyne, UK , while
monoclonal antibodies VIA4 to a-dystroglycan,1
XIXC2 to 427 kDa dystrophin and C464.6 to a -1
NaqrKq-ATPase were from Upstate Biotechnology
 .Lake Placid, NY, USA .
2.3. Membrane preparations
Homogenates from diaphragm, hind leg muscle
and heart from New Zealand white rabbits were used
to prepare crude microsomal membranes using stan-
w xdard differential centrifugation techniques 16,47 .
Rabbit brain synaptosomes were prepared according
w xto the method of Gordon-Weeks 50 . In order to
minimize protein degradation, all isolation procedures
were performed at 0–48C and all buffers contained
the following protease inhibitors: 0.15 mM aprotinin,
0.3 mM E-64, 1 mM leupeptin, 0.2 mM pefabloc, 1.4
mM pepstatin A, 0.5 mM soybean trypsin inhibitor,
and 1 mM EDTA. Protein concentration was deter-
w xmined by the method of Bradford 51 with rat my-
ofibrillar proteins as a standard.
2.4. Extraction procedures
To determine the basic biochemical properties of
b-dystroglycan, diaphragm and brain membranes
were extracted by detergent solubilization using 1%
 . w xvrv Triton X-100 19,52 and alkaline extraction
was performed at pH 11 as described previously in
w xdetail 19,52 . Following solubilization, membranes
were centrifuged for 20 min at 150,000=g and then
separated fractions were analyzed by immuno-
blotting.
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2.5. Chemical crosslinking
Following isolation, membranes were immediately
chemically crosslinked and then electrophoretically
analyzed. Membrane vesicles were incubated at room
temperature for 30 min with 10 to 200 mg crosslinker
per mg protein at pH 8.0 as previously described in
˚w xdetail 47 . To prepare stock solutions of the 12 A
w xprobe dithiobis-succinimidyl propionate 48 , hy-
drophobic crosslinker was dissolved in dimethyl sul-
foxide. The final dimethyl sulfoxide concentration in
 .membrane suspensions did not exceed 4% vrv .
Crosslinking was terminated by the addition of 50 ml
of 1 M ammonium acetate per ml reaction medium
and then an equal volume of sodium dodecyl sulfate-
w xcontaining sample buffer 53 was added prior to
electrophoretic separation.
2.6. Gel electrophoresis and immunoblot analysis
Electrophoretic separation of proteins was per-
formed for 2000 V h in a Hoefer SE-600 system
Hoefer Scientific Instruments, San Francisco, CA,
.USA using sodium dodecyl sulfate-containing 4–
 . w x16% wrv gradient polyacrylamide gels 53 . Since
very large protein complexes did not properly enter
the separating gel after chemical crosslinking, routine
gel electrophoretic analysis of crosslinked proteins
was carried out in resolving gels which lacked a
stacking gel system. Titin, nebulin and myosin from
rat myofibrillar preparations served as high molecular
w xmass markers 47 . Electrophoretically separated pro-
w xteins were transferred to nitrocellulose 54 using a
TE-52X transfer unit from Hoefer Scientific Instru-
 .ments San Francisco, CA, USA . Blocking and incu-
bation of nitrocellulose sheets was performed by
w xestablished procedures 16,47 whereby primary and
secondary antibodies were used at a dilution of 1:1000
and 1:3000, respectively. Immuno-reactive bands
were visualized using the enhanced chemilumines-
cence kit from Boehringer Mannheim Lewis, East
.Sussex, UK .
2.7. Immunofluorescence microscopy
Staining of 10 mm transverse cryosections from
rabbit diaphragm and gastrocnemius muscle was per-
formed with monoclonal antibody NCL-43 to b-dys-
troglycan and a polyclonal antibody to a peptide
representing the last 15 amino acids of human skele-
w xtal muscle dystrophin 32 . Primary and secondary
antibodies were used at a dilution of 1:100 and 1:150,
respectively. Preparation, blocking, incubation and
washing of cryosections, as well as photography was
carried out by standard procedures as already de-
w xscribed in detail elsewhere 35 .
3. Results
3.1. Characterization of the dystrophin-associated
glycoprotein b-dystroglycan
Since investigation of the trans-plasmalemmal
linkage between dystrophin and laminin-a 2 via the
dystroglycan complex up to now has been mainly
limited to skeletal muscle fibers, we examined the
basic biochemical properties of b-dystroglycan in the
diaphragm and the brain. Standard extraction proce-
dures using non-ionic detergent or alkaline treatment
confirmed that this dystrophin-associated glyco-
protein exhibits properties of a typical integral mem-
brane protein also in these two tissues. As illustrated
in Fig. 1a, incubation with Triton X-100 solubilized
b-dystroglycan from diaphragm microsomes, but al-
kaline extraction left it with the bilayer fraction. The
same results were obtained with solubilization experi-
ments using rabbit brain membrane preparations. Im-
muno-reactive bands representing the dystrophin-as-
sociated glycoprotein of 43 kDa were mostly detected
in the detergent-extracted fraction and the synaptoso-
 .mal pellets following alkaline treatment Fig. 1b .
Extensive cellular localization studies of the dys-
trophin- and utrophin–glycoprotein complexes are
mostly restricted to skeletal muscles. Thus prior to
our crosslinking analysis of diaphragm membranes,
we verified the plasmalemmal localization of b-dys-
troglycan in this tissue. Indirect immunofluorescence
microscopy clearly revealed that the antigen recog-
nized by monoclonal antibody NCL-43 is not only
localized to the sarcolemma of gastrocnemius fibers
 .Fig. 2d , but is also almost exclusively found in the
 .cell periphery of rabbit diaphragm Fig. 2b . As
already established for rabbit skeletal muscle, b-dys-
troglycan co-localized with the dystrophin of 427
kDa in the plasma membrane of transversely cut
 .diaphragm cryosections Fig. 2a,b . Surface staining
( )D.M. Finn, K. OhlendieckrBiochimica et Biophysica Acta 1370 1998 325–336 329
Fig. 1. Immunodetection of b-dystroglycan from rabbit di-
aphragm and brain following non-ionic detergent treatment or
alkaline extraction. Shown are immunoblots of microsomal mem-
 .  .branes isolated from rabbit diaphragm a and brain b ho-
mogenates stained with monoclonal antibody NCL-43 to b-dys-
troglycan. The majority of b-dystroglycan is found in the deter-
 .gent-extracted supernatant fraction lane 3 and the non-alkaline
 .sensitive bilayer fraction lane 4 as compared to the untreated
 . microsomal fraction lane 1 , the detergent-insoluble pellet lane
.  .2 and the alkaline-extracted supernatant fraction lane 5 . This
relative insolubility in alkaline solutions and easy extraction with
non-ionic detergents confirms that b-dystroglycan behaves bio-
chemically like a typical integral membrane protein, as predicted
w xby its cDNA sequence 11 . Arrows indicate the position of the
 .immunodecorated 43 kDa band of b-dystroglycan b-DG .
of the diaphragm was specific, since control sections
incubated with fluorescein-labeled secondary antibod-
ies only, did not exhibit significant background stain-
 .ing not shown . It has previously been shown that
b-dystroglycan is associated with blood vessels in
w xbrain 34,44 . However, using monoclonal antibody
NCL-43, we did not observe enough specific staining
patterns in brain for proper interpretation of the sub-
cellular localization of b-dystroglycan. Since im-
munofluorescence labeling of rabbit brain sections
did not result in sufficient staining above background
levels, this project was not further pursued.
3.2. Chemical crosslinking of b-dystroglycan from
diaphragm, skeletal muscle and heart
The dystrophin–glycoprotein complex is of ex-
tremely large size and therefore our oligomerization
studies had to take into account the potentially very
limited electrophoretic mobility of chemically
crosslinked membrane complexes. Initial studies
showed that conventional gel systems employing a
stacking gel did not reveal satisfactory results since
dystrophin-associated components did not properly
enter the resolving gel andror were not sufficiently
Fig. 2. Distribution of b-dystroglycan in rabbit diaphragm and skeletal muscle. Indirect immunofluorescence labeling of transverse
 .  .  .cryosections from rabbit diaphragm a, b and gastrocnemius muscle c, d was performed with primary antibodies to dystrophin a, c
 .and b-dystroglycan b, d and fluorescein-conjugated secondary antibodies. Both primary antibodies stained in both tissues almost
exclusively the cell periphery, while control experiments with secondary antibody only did not result in plasmalemma labeling. Bar equals
20 mm.
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transferred from the stacking gel system onto nitro-
cellulose. However, since the unequivocal identifica-
tion of b-dystroglycan depended on immunoblotting
of electrophoretically separated protein complexes, a
gel system lacking a stacking gel was tried out and
found to be superior in the detection of very high
molecular mass complexes. While increasing amounts
of crosslinker resulted, in both gel systems not
.shown , in a clearly detectable decrease in the b-dys-
troglycan monomer of apparent 43 kDa, only the
immunoblots from gels which lacked a stacking gel
exhibited high molecular mass complexes of this
 .glycoprotein Fig. 3a–c . Since the lack of linearity
between the relative electrophoretic mobility and the
molecular mass of very large protein bands prevented
a proper determination of the apparent size of the
oligomeric complexes, the relative molecular mass of
the crosslinked complexes could only be estimated to
be approximately 2000 kDa. Diaphragm, skeletal
muscle and heart microsomes exhibited a very com-
parable shift of b-dystroglycan to a much reduced
electrophoretic mobility following crosslinking with a
˚  .hydrophobic 12 A crosslinker Fig. 3a–c .
3.3. Chemical crosslinking analysis of b-dystrogly-
can, a-dystroglycan, dystrophin and laminin in
diaphragm and skeletal muscle
Crosslinker to protein ratios were chosen so as to
avoid artifacts of general protein clustering. At a
concentration of 10 to 200 mg crosslinker per mg
membrane protein no general shifts to higher molecu-
lar masses were observed. Coomassie-stained protein
gels revealed only decreases in the relative elec-
trophoretic mobility of distinct subsets of membrane
 .proteins not shown . Incubation of diaphragm mem-
branes with 10 mg dithiobis-succinimidyl propionate
per mg protein resulted in a dramatic decrease in the
43 kDa monomer of b-dystroglycan and in the con-
current appearance of a very high molecular mass
protein band recognized by monoclonal antibody
 .NCL-43 Fig. 4a . Similar shifts to a greatly reduced
electrophoretic mobility were observed for peripheral
a-dystroglycan of 156 kDa, the basement component
laminin and the membrane cytoskeletal protein dys-
 .trophin of 427 kDa Fig. 4b–d . All four key compo-
nents of the dystrophin–glycoprotein complex exhib-
Fig. 3. Chemical crosslinking of b-dystroglycan in microsomes from rabbit diaphragm, skeletal muscle and heart. Shown are
 .  .  .immunoblots of crosslinked microsomes from rabbit diaphragm a , skeletal muscle b and heart c stained with monoclonal antibody
 .NCL-43 to b-dystroglycan b-DG . Lanes 1 to 5 represent 0, 10, 50, 100 and 200 mg of crosslinker per mg membrane protein,
 .respectively. Nitrocellulose transfers were obtained from non-reducing 4–16% wrv gradient gels run without a stacking gel system. The
 .arrow indicates the position of the 43 kDa b-dystroglycan b-DG monomer, while an arrow head marks the position of high molecular
 y3.mass complexes following crosslinking. Molecular mass markers =10 are indicated on the left.
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Fig. 4. Chemical crosslinking of the dystroglycan complex in
microsomes from rabbit diaphragm. Shown are immunoblots of
crosslinked microsomes from rabbit diaphragm stained with mon-
 .  .oclonal antibodies NCL-43 to b-dystroglycan b-DG a , VIA41
 .  .to a-dystroglycan a-DG b and XIXC2 to 427 kDa dystrophin
 .  .DYS-427 d , as well as a polyclonal antibody to laminin
 .  .LAM c . Lanes 1 to 5 represent 0, 10, 50, 100 and 200 mg of
crosslinker per mg membrane protein, respectively. Nitrocellu-
 .lose transfers were obtained from non-reducing 4–16% wrv
gradient gels run without a stacking gel system. Arrows indicate
the position of monomers, while arrow heads mark the position
of high molecular mass complexes following crosslinking.
 y3.Molecular mass markers =10 are indicated on the left.
ited a distinct overlap in immunoreactivity. Im-
munoblotting with antibodies to adhalin a-
.sarcoglycan , a member of the sarcoglycan subcom-
plex, did not result in strong enough labeling for
proper interpretation of oligomerization following
 .crosslinking not shown . Increasing amounts of
crosslinker caused no further decrease in elec-
trophoretic mobility of the members of the dys-
 .trophin–glycoprotein complex studied Fig. 4a–d .
Monomers of a-dystroglycan, laminin and dys-
trophin were relatively weakly labeled by their re-
spective antibodies, possibly due to their low abun-
dance in the diaphragm membrane preparations.
However, for an accurate crosslinking analysis it was
necessary to perform our experiments with crude,
non-salt washed microsomes so as to avoid potential
artifacts introduced by excessive density gradient
Fig. 5. Chemical crosslinking of the dystroglycan complex in
microsomes from rabbit skeletal muscle. Shown are immunoblots
of crosslinked microsomes from rabbit skeletal muscle stained
 .with monoclonal antibodies NCL-43 to b-dystroglycan b-DG
 .  .  .a , VIA41 to a-dystroglycan a-DG b and XIXC2 to 427 kDa
 .  .dystrophin DYS-427 d , as well as a polyclonal antibody to
 .  .laminin LAM c . Lanes 1 to 5 represent 0, 10, 50, 100 and 200
mg of crosslinker per mg membrane protein, respectively. Nitro-
cellulose transfers were obtained from non-reducing 4–16%
 .wrv gradient gels run without a stacking gel system. Arrows
indicate the position of monomers, while arrow heads mark the
position of high molecular mass complexes following cross-
 y3.linking. Molecular mass markers =10 are indicated on the
left.
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Fig. 6. Chemical crosslinking of the dystroglycan complex in
microsomes from rabbit brain. Shown are immunoblots of
crosslinked synaptosomes from rabbit brain stained with mono-
 .  .clonal antibodies NCL-43 to b-dystroglycan b-DG a , VIA41
 .  .to a-dystroglycan a-DG b and VC1.1 to the HNK-1 antigen
 .  .  .HNK-1 c , as well as polyclonal antibodies to laminin LAM
 .  .  .d and 116 kDa brain dystrophin Dp116 e . Lanes 1 to 5
represent 0, 10, 50, 100 and 200 mg of crosslinker per mg
membrane protein, respectively. Nitrocellulose transfers were
 .obtained from non-reducing 4–16% wrv gradient gels run
without a stacking gel system. Arrows indicate the position of
monomers, while arrow heads mark the position of high molecu-
lar mass complexes following crosslinking. Molecular mass
 y3.markers =10 are indicated on the left.
centrifugation or subcellular affinity purification. In
skeletal muscle, very comparable results to those of
the diaphragm were obtained. Chemical crosslinking
caused a shift to higher relative molecular masses for
all members of the dystrophin–glycoprotein complex
 .analyzed Fig. 5a–d . A definite overlap between
immunoreactive bands representing b-dystroglycan,
a-dystroglycan, laminin and dystrophin was estab-
lished.
3.4. Chemical crosslinking analysis of b-dystrogly-
can, a-dystroglycan, Dp116 and laminin in brain
In synaptosomes, b-dystroglycan of 43 kDa exhib-
ited a distinct shift to very high molecular mass
complexes after chemical crosslinking. A decrease in
monomer staining and an increase in labeling of
oligomeric complexes was synchronous in appear-
 .ance Fig. 6a . Labeling of the 156 kDa monomer of
 .a-dystroglycan was extremely weak not shown , but
a clear overlap of immuno-reactivity was observed
for both dystroglycans following crosslinking Fig.
.6b . A shift of a-dystroglycan to higher molecular
mass complexes following crosslinking was indicated
by immunoblotting with a monoclonal antibody which
 .recognizes the HNK-1 epitope Fig. 6c . The fact that
a-dystroglycan contains the HNK-1 epitope was re-
w xcently established by Yamada et al. 55 . However,
other proteins such as the neuronal cell adhesion
molecule might also be recognized by this mono-
clonal antibody. Antibodies to laminin showed suffi-
cient staining of monomers and oligomers of this
basement membrane component and the oligomeric
band exhibited an overlap with a- and b-dystrogly-
 .can Fig. 6d . With respect to brain dystrophin iso-
forms, Dp116 appears to be of relatively high abun-
dance in synaptosomal vesicles. Our affinity-purified
antibody to the extreme COOH-terminus of dys-
trophin recognized this protein of apparent 116 kDa
 .extremely well Fig. 6e . Increasing amounts of
chemical crosslinking of synaptosomes resulted in a
marked decrease in the immunolabeling of the
monomer band and concurrently produced the ap-
pearance of a high molecular mass oligomeric com-
plex. The Dp116 band with decreased electrophoretic
mobility showed a potential overlap with the im-
muno-reactive bands representing laminin and the
 .dystroglycans Fig. 6a–d . Immunoblotting of
crosslinked brain membranes with antibodies to 427
kDa dystrophin and 395 kDa utrophin did not reveal
 .satisfactory labeling not shown and the potential
complex formation of this minor brain dystrophin
isoform and its autosomal homologue with the dys-
troglycan proteins could thus not be investigated.
Results from control experiments as illustrated in
Fig. 7 demonstrate the specificity of the immunologi-
cal overlap between members of the dystrophin–
glycoprotein complexes in skeletal muscle, di-
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Fig. 7. Chemical crosslinking of microsomes from rabbit skeletal
muscle, diaphragm and brain. Shown are control immunoblots of
 .crosslinked membranes from rabbit skeletal muscle a , di-
 .  .aphragm b and brain c, d stained with monoclonal antibodies
 . q qSB-SP-1 to spectrin a, b, d and C464.6 to a -Na rK -ATPase1
 .c . Lanes 1 to 5 represent 0, 10, 50, 100 and 200 mg of
crosslinker per mg membrane protein, respectively. Nitrocellu-
 .lose transfers were obtained from non-reducing 4–16% wrv
gradient gels run without a stacking gel system. Arrows indicate
 y3.the position of monomers. Molecular mass markers =10 are
indicated on the left.
aphragm and brain following chemical crosslinking
 .Figs. 4–6 . Immunodecoration of the 220 kDa
monomer of the membrane cytoskeletal component
spectrin decreases with increasing amounts of
crosslinker used, but no high molecular mass band is
detectable in the region of the crosslinked b-dys-
troglycan protein band. While the crosslinking-
induced decrease in the relative abundance of spec-
trin monomers is very pronounced for skeletal muscle
 .  .Fig. 7a and diaphragm Fig. 7b membranes, brain
synaptosomes exhibit a much less prominent reduc-
tion in immunodecoration of the apparent 220 kDa
 .band Fig. 7d . Thus, brain spectrin does not appear
to be extensively crosslinkable using 10 to 100 mg
DSP per mg protein which clearly induces complex
formation of dystrophin-associated glycoproteins Fig.
.6 . The lack of high molecular mass bands containing
spectrin could be due to the failure of very large
spectrin complexes to be able to enter the gel system
 .employed or possibly the epitope s recognized by
monoclonal antibody SB-SP-1 were destroyed during
the crosslinking process. The fact that the immuno-
logical overlap between dystrophin and dystrophin-
associated glycoproteins is specific is furthermore
w xdemonstrated by previously published findings 47 .
Crosslinking of rabbit skeletal muscle membranes,
under the same conditions as employed here, does not
result in an immunoreactive overlap between dys-
trophin-associated proteins and various muscle mem-
brane proteins present in crude microsomal fractions
including the surface dihydropyridine receptor. Com-
plexes between ryanodine receptor tetramers and a -1
subunits of the transverse tubular dihydropyridine
w xreceptor are larger in relative molecular mass 47
than the dystrophin–glycoprotein complexes de-
scribed here. With respect to brain membranes, stain-
ing of the a -subunit of the NaqrKq-ATPase showed1
a marked decrease of the 110 kDa monomer follow-
ing chemical crosslinking using dithiobis-succi-
 .nimidyl propionate Fig. 7c . However, as already
observed for spectrin, no appearance of a high molec-
ular mass band containing this ubiquitous surface
membrane marker was observed in the region of
 .crosslinked b-dystroglycan Fig. 7c . Therefore, the
results presented in Figs. 4–6 strongly suggest that
b-dystroglycan does not exist as a monomer in native
membranes and that the immunological overlap with
other members of the dystrophin–glycoprotein com-
plex is a specific result of chemical crosslinking of
surface membrane proteins which have a very close
neighbourhood relationship.
4. Discussion
Although early symptoms of Duchenne muscular
dystrophy include a decrease in strength of limb and
torso muscles, the great majority of patients die of
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w xrespiratory and cardiac failure 26 . In addition, cog-
nitive impairments may be the primary manifestation
of the disease process preceding muscular weakness
w x26 . This lends central importance to studies into
dystrophin-associated glycoproteins in diaphragm and
brain with respect to understanding the overall patho-
w xgenesis of muscular dystrophies 8,9 . Considering
the world-wide efforts to develop suitable therapeutic
strategies for the treatment of inherited diseases such
w xas muscular dystrophies 56 , it is important to take
into account the complex nature of the pathophysio-
logical mechanisms occurring down-stream from the
 .initial genetic defect s . Efficient up-regulation of
dystrophin and its isoforms by myoblast or gene
transfer therapies in muscular dystrophy patients is
w xstill elusive 57,58 . For gene therapy to be successful
the pathophysiological problems in tissues such as
the diaphragm and nervous system have also to be
addressed. In this respect, elucidation of the normal
cellular functions of diaphragm and brain dystrophins
and its associated glycoproteins might shed light on
respiratory and neuronal abnormalities associated with
certain neuromuscular disorders.
Based on biochemical studies and its cDNA se-
quence, skeletal muscle b-dystroglycan is predicted
wto be a glycosylated transmembrane protein 2,10–
x12,20 . Here, we could clearly show that diaphragm
and brain b-dystroglycans also exhibit properties typ-
ical of integral membrane proteins. With respect to
solubility in non-ionic detergent and resistance to
alkaline extraction procedures, diaphragm and brain
b-dystroglycan behave in an exactly opposite way to
w x w xdystrophin 19 , utrophin 52 and the dystrophin
w xbrain isoform Dp116 32 . These findings agree with
the current model of the dystrophin–glycoprotein
w xcomplex 7–9 which assumes a membrane cyto-
skeletal function for dystrophin isoforms and a trans-
w xplasmalemma spanning role for b-dystroglycan 10 .
Binding of laminin-a 2 by peripheral a-dystroglycan
has been demonstrated by overlay assays, but highly
purified preparations of the dystrophin–glycoprotein
complex from skeletal muscle fibers are essentially
w xdevoid of the a 2-chain-containing laminin-2 2,20 .
However, here we could show by chemical cross-
linking of skeletal muscle microsomes that laminin-
a 2 and the dystroglycans exist in a very close neigh-
borhood relationship. This confirms the prediction
that 427 kDa dystrophin is an integral part of a
surface membrane system that links the sub-sarco-
lemmal membrane cytoskeleton and the extracellular
w xbasement membrane 7–9 . Approximately the same
size dystrophin-associated complexes were found in
skeletal muscle and diaphragm preparations follow-
ing crosslinking, indicating that very similar spatial
configurations might be present in the two different
tissues. Therefore dystrophin may have the same
function in diaphragm as in skeletal and heart muscle
and disruption of its proper organization in muscular
dystrophy could be the initial step in the pathophysio-
logical processes rendering all muscular tissues more
w xsusceptible to necrosis 8,9 .
In contrast to skeletal muscle fibers, very little is
known about the function of brain dystrophins and
dystrophin-associated proteins and their fate during
w xmuscular dystrophies 27–34,42–45 . The cross-
linking analysis presented here indicates that in
synaptosomes both a-dystroglycan of 156 kDa and
b-dystroglycan of 43 kDa form a complex. In anal-
ogy to the muscle dystrophin–glycoprotein complex,
laminin was also found to exist in a close neighbour-
hood relationship to the dystroglycans. It is unclear
how and with which brain laminin isoform a-dys-
troglycan and thus indirectly b-dystroglycan may
w xinteract in synaptosomes. Since Tian et al. 44 could
show that brain a-dystroglycan and a 2-chain-con-
taining laminin-2 can interact, we presume that both
dystroglycans and the laminin-2 isoform are integral
parts of this proposed brain complex. However, stud-
w xies by Mummery et al. 42 indicate that b-dys-
troglycan, although present in synaptic membranes, is
not detectable in the postsynaptic density fraction of
rat forebrain. This would exclude a major link be-
tween 427 kDa brain dystrophin and b-dystroglycan
in the postsynaptic density. On the other hand, little
is known about the subcellular localisation of the
other brain dystrophin isoform, Dp116, which was
investigated in this report. Dp116 might have a
broader synaptic distribution than the less abundant
427 kDa dystrophin.
Since immuno-decoration for Dp116 overlapped
with that of the dystroglycans, these components
might form a complex within a synaptic region other
than the postsynaptic density. However, currently, it
cannot be concluded that b-dystroglycan, a-dys-
troglycan, Dp116 and utrophin are all closely linked
at only one specific subcellular region in brain tis-
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sues. It is however clear that Dp116, since it is
lacking the N-terminal actin-binding domain of 427
w xkDa skeletal muscle dystrophin 6 , cannot be in-
volved in anchoring a cortical actin membrane cyto-
skeleton to the brain cell surface. A potential indirect
connection of Dp116 with the extracellular matrix of
brain cells could have a similar function as proposed
for the muscular dystrophin–glycoprotein complex
and the neuromuscular utrophin–glycoprotein com-
plex, namely stabilization of the surface membrane
andror anchoring of peripheral receptor molecules
w x8,9 . Our crosslinking studies of synaptosomes iso-
lated from brain tissue is in agreement with reports
w xby Yamada et al. 55,59 who described a complex
formation of Dp116 in peripheral nerve using laminin
affinity chromatography. Thus, Dp116 appears to
form a linkage with some of the glycoproteins origi-
nally described in skeletal muscle both in the central
and peripheral nervous system. Recently, it was sug-
gested that this interaction between a-dystroglycan
and laminin is at least partially mediated by complex
w xcarbohydrate moities on dystroglycan 60 .
The overall spatial configuration of dystrophin–
glycoprotein complexes, based on extensive studies
into the structure of dystrophin and its many associ-
w xated surface components 6–10 , is confirmed by the
chemical crosslinking data as presented in this report.
In the periphery of fibers from skeletal muscle, heart
and diaphragm, the plasmalemma-spanning dystro-
glycan complex is in close contact with sarcoglycans,
dystrophin and the cortical actin membrane cyto-
skeleton, as well as laminin-a 2. Besides dystrophin,
a major cytoskeletal anchor in the neuromuscular
junction appears to be utrophin which exists also in
close association with the same set of surface glyco-
w xproteins 61 . In contrast, sarcoglycans do not appear
w xto be present in brain tissues 41 and possibly the
major brain dystrophin isoform Dp116 is an integral
part of a surface membrane complex including
laminin-a 2 and the two dystroglycans. Since di-
aphragm dystrophin of 427 kDa is missing in muscu-
lar dystrophy patients, a disruption of the dystrogly-
can-complex might destabilize the diaphragm fiber
periphery and cause an impaired respiratory function.
Whether abnormalities in various brain dystrophin
isoforms play a direct or indirect role in cognitive
impairment of Duchenne muscular dystrophy patients
and which dystrophins and dystrophin-associated pro-
teins are complexed at which synaptic regions re-
mains to be determined.
Acknowledgements
Research was funded by the Health Research
Board, Dublin and Muscular Dystrophy Ireland. We
wish to thank John Perryman for technical assistance.
References
w x1 A.P. Monaco, R.L. Neve, C. Coletti-Feener, C.J. Bertelson,
 .D.M. Kurnit, L.M. Kunkel, Nature 323 1986 646–650.
w x2 J.M. Ervasti, K. Ohlendieck, S.D. Kahl, M.G. Gaver, K.P.
 .Campbell, Nature 345 1990 315–319.
w x3 M. Yoshida, A. Suzuki, H. Yamamoto, S. Noguchi, Y.
 .Mizuno, E. Ozawa, Eur. J. Biochem. 222 1994 1055–1061.
w x4 D.J. Blake, J.M. Tinsley, K.E. Davies, Trends Cell Biol. 4
 .1994 19–23.
w x5 J.M. Tinsley, D.J. Blake, M. Pearce, A.E. Knight, J.
Kendrick-Jones, K.E. Davies, Curr. Opin. Genet. Dev. 3
 .1993 484–490.
w x  .6 A.H. Ahn, L.M. Kunkel, Nat. Genet. 3 1993 283–291.
w x  .7 J.M. Ervasti, K.P. Campbell, Curr. Opin. Cell Biol. 5 1993
82–87.
w x  .8 K.P. Campbell, Cell 80 1995 675–679.
w x  .9 K. Ohlendieck, Eur. J. Cell Biol. 69 1996 1–10.
w x  .10 M.D. Henry, K.P. Campbell, Curr. Opin. Cell Biol. 8 1996
625–631.
w x11 O. Ibraghimov-Beskrovnaya, J.M. Ervasti, C.J. Leveille,
C.A. Slaughter, S.W. Sernett, K.P. Campbell, Nature 355
 .1992 696–702.
w x12 O. Ibraghimov-Beskrovnaya, A. Milatovich, T. Ozcelik, B.
Yang, K. Koepnick, U. Franke, K.P. Campbell, Hum. Mol.
 .Genet. 2 1993 1651–1657.
w x13 D. Jung, B. Yang, J. Meyer, J.S. Chamberlain, K.P. Camp-
 .bell, J. Biol. Chem. 270 1995 27305–27310.
w x14 G. Dickson, A. Azad, G.E. Morris, H. Simon, M. Nour-
 .sadeghi, F.S. Walsh, J. Cell Sci. 103 1992 1223–1233.
w x  .15 J.M. Ervasti, K.P. Campbell, J. Cell Biol. 122 1993 809–
823.
w x16 K. Ohlendieck, J.M. Ervasti, J.B. Snook, K.P. Campbell, J.
 .Cell Biol. 112 1991 135–148.
w x17 M.J. Cullen, J. Walsh, L.V.B. Nicholson, Acta Neuropathol.
 .87 1994 349–354.
w x18 T.R. Helliwell, T.M. Nguyen, G.E. Morris, Neuromuscular
 .Disord. 4 1994 101–113.
w x  .19 K. Ohlendieck, K.P. Campbell, FEBS Lett. 283 1991
230–234.
w x  .20 J.M. Ervasti, K.P. Campbell, Cell 66 1991 1121–1131.
w x21 K. Ohlendieck, K. Matsumura, V.V. Ionasescu, J.A. Tow-
bin, E.P. Bosch, S.L. Weinstein, S.W. Sernett, K.P. Camp-
 .bell, Neurology 43 1993 795–800.
( )D.M. Finn, K. OhlendieckrBiochimica et Biophysica Acta 1370 1998 325–336336
w x22 S.L. Roberds, F. Leturcq, V. Allamand, F. Piccolo, M.
Jeanpierre, R.D. Anderson, L.E. Lim, J.C. Lee, F.M.S.
Tome, N.B. Romero, M. Fardeau, J.S. Beckmann, J.C.
 .Kaplan, K.P. Campbell, Cell 78 1994 625–633.
w x23 C.G. Bonnemann, R. Modi, S. Noguchi, Y. Mizuno, M.¨
Yoshida, E. Gussoni, E.M. McNally, D.J. Duggan, C. An-
gelini, E.P. Hoffman, E. Ozawa, L.M. Kunkel, Nat. Genet.
 .11 1995 266–272.
w x24 S. Noguchi, E.M. McNally, K.B. Othmane, Y. Hagiwara, Y.
Mizuno, M. Yoshida, H. Yamamoto, C.G. Bonnemann, E.¨
Gussoni, P.H. Denton, T. Kyriakides, L. Middelton, F.
Hentai, M.B. Hamida, I. Nonaka, J.M. Vance, L.M. Kunkel,
 .E. Ozawa, Science 270 1995 819–822.
w x25 M.A. Salih, Y. Sunada, M. Al-Nasser, C.O. Ozo, M.H.
Al-Turaiki, M. Akbar, K.P. Campbell, Ann. Neurol. 40
 .1996 925–928.
w x26 A.E.H. Emery, Duchenne muscular dystrophy, Oxford
Monographs on Medical Genetics No. 24, Oxford Univ.
Press, Oxford, 1993.
w x27 T.W. Kim, K. Wu, J.L. Xu, I.B. Black, Proc. Natl. Acad.
 .Sci. U.S.A. 89 1992 11642–11644.
w x28 N. Bresolin, E. Castelli, G.P. Comi, G. Felisari, A. Bardoni,
D. Perani, F. Grassi, A. Turconi, F. Mazzuchelli, D. Gal-
lotti, M. Moggio, A. Prelle, C. Ausenda, G. Fazio, G.
 .Scarlato, Neuromuscular Disord. 4 1994 359–369.
w x  .29 T.W. Kim, K. Wu, I.B. Black, Ann. Neurol. 38 1995
446–449.
w x30 H.G.W. Lidov, T.J. Byers, S.C. Watkins, L.M. Kunkel,
 .Nature 348 1990 725–728.
w x31 H.G.W. Lidov, T.J. Byers, L.M. Kunkel, Neuroscience 54
 .1993 167–187.
w x  .32 D.M. Finn, K. Ohlendieck, Neurosci. Lett. 222 1997 25–
28.
w x33 T.S. Khurana, S.C. Watkins, L.M. Kunkel, J. Cell Biol. 119
 .1992 357–366.
w x34 T.S. Khurana, L.M. Kunkel, A.D. Frederickson, S. Car-
 .bonetto, S.C. Watkins, J. Cell Sci. 108 1995 173–185.
w x35 K. Ohlendieck, J.M. Ervasti, K. Matsumura, S.D. Kahl, C.J.
 .Leveille, K.P. Campbell, Neuron 7 1991 499–508.
w x36 T.M. Nguyen, J.M. Ellis, D.R. Love, K.E. Davies, K.C.
 .Gatter, G.E. Morris, J. Cell Biol. 115 1991 1695–1700.
w x37 F. Pons, N. Augier, J.O.C. Leger, A. Roberts, F.M.S. Tome,
M. Fardeau, T. Voit, L.V.B. Nicholson, D. Mornet, J.J.
 .Leger, FEBS Lett. 282 1991 161–165.
w x38 S.H. Gee, F. Montanaro, M.H. Lindenbaum, S. Carbonetto,
 .Cell 77 1994 675–686.
w x39 J.T. Campanelli, S.L. Roberds, K.P. Campbell, R.H.
 .Scheller, Cell 77 1994 663–674.
w x40 M.A. Bowe, K.A. Deyst, J.D. Leszyk, J.R. Fallon, Neuron
 .12 1994 1173–1180.
w x41 H. Yamomoto, Y. Mizuno, N. Ikuya, M. Yoshida, E. Ozawa,
 .J. Biochem. 115 1994 162–167.
w x42 R. Mummery, A. Sessay, F.A. Lai, P.W. Beesley, J. Neu-
 .rochem. 66 1996 2455–2459.
w x43 F. Montanaro, S. Carbonetto, K.P. Campbell, M. Linden-
 .baum, J. Neurosci. Res. 42 1995 528–538.
w x44 M. Tian, C. Jacobson, S.H. Gee, K.P. Campbell, M. Jucker,
 .Eur. J. Neurosci. 8 1996 2739–2747.
w x45 D.C. Gorecki, H. Abdulrazzak, K. Lukasiuk, E.A. Barnard,
 .Eur. J. Neurosci. 9 1997 965–976.
w x46 S.S. Wong, Chemistry of Protein Conjugation and
Crosslinking, CRC Press, Boca Raton, FL, 1991.
w x  .47 B.E. Murray, K. Ohlendieck, Biochem. J. 324 1997 689–
696.
w x  .48 A.G. Lomant, G. Fairbanks, J. Mol. Biol. 104 1976 243–
261.
w x49 S.K. Powell, H.K. Kleinman, Int. J. Biochem. Cell Biol. 28
 .1997 401–414.
w x  .50 P.R. Gordon-Weeks, in: A.J. Turner, H.S. Bachelard Eds. ,
Neurochemistry, a Practical Approach, IRL Press, Oxford,
pp. 1–26.
w x  .51 M.M. Bradford, Anal. Biochem. 72 1976 248–254.
w x  .52 K. Ohlendieck, Biochim. Biophys. Acta 1283 1996 215–
222.
w x  .53 U.K. Laemmli, Nature 227 1970 680–685.
w x54 H.T. Towbin, T. Staehlin, J. Gordon, Proc. Natl. Acad. Sci.
 .U.S.A. 76 1979 4350–4354.
w x55 H. Yamada, A. Chiba, T. Endo, A. Kobata, L.V. Anderson,
H. Hori, H. Fukuta-Ohi, I. Kanazawa, K.P. Campbell, T.
 .Shimizu, K. Matsumura, J. Neurochem. 66 1996 1518–
1524.
w x56 C.G. Bonnemann, E.M. McNally, L.M. Kunkel, Curr. Opin.¨
 .Pediatr. 8 1996 569–582.
w x  .57 T.A. Partridge, K.E. Davies, Br. Med. Bull. 51 1995
123–137.
w x  .58 K. Inui, S. Okada, G. Dickson, Brain Dev. 18 1996
357–361.
w x59 H. Yamada, A.J. Denzer, H. Hori, T. Tanaka, L.V. Ander-
son, S. Fujita, H. Fukuta-Ohi, T. Shimizu, M.A. Ruegg, K.
 .Matsumura, J. Biol. Chem. 271 1996 23418–23423.
w x60 A. Chiba, K. Matsumura, H. Yamada, T. Inazu, T. Shimizu,
S. Kusunoki, I. Kanazawa, A. Kobata, T. Endo, J. Biol.
 .Chem. 272 1997 2156–2162.
w x61 K. Matsumura, J.M. Ervasti, K. Ohlendieck, S.D. Kahl, K.P.
 .Campbell, Nature 360 1992 588–591.
